格隆汇8月19日丨三爱健康集团(01889.HK)公告，集团截至2025年6月30日止6个月未经审核管理账目的 初步审阅，与2024年同期公司拥有人应占溢利约人民币980万元相比，公司将产生公司拥有人应占亏损 人民币1150万元至人民币1400万元。 由公司拥有人应占溢利转为公司拥有人应占亏损的预期变动主要由于：(i)公司已于2024年同期录得出售 附属公司的大额一次性非经常性收益净额约人民币1704万元；(ii)公司已于本期间入账北京航洋健康科 技有限公司及其附属公司应占分销成本及行政开支增加约人民币460万元，其主要部分并无于2024年同 期入账。 ...

由公司拥有人应占溢利转为公司拥有人应占亏损的预期变动主要由于：公司已于2024年同期取得出售附 属公司的大额一次性非经常性收益净额约人民币1704万元;及公司已于本期间入账北京航洋健康科技有 限公司及其附属公司应占分销成本及行政开支增加约人民币460万元，其主要部分并无于2024年同期入 账。 三爱健康集团(01889)发布公告，与2024年同期公司拥有人应占溢利约人民币980万元相比，截至2025年 6月30日止六个月公司将产生公司拥有人应占亏损介于人民币1150万元至1400万元。 ...

三愛健康產業集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1889） 盈利警告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因依賴該等內容 而引致的任何損失承擔任何責任。 Sanai Health Industry Group Company Limited 董事會預期，本集團截至二零二五年六月三十日止六個月的中期業績公告將於二零 二五年八月底前刊發。 股東及本公司潛在投資者於買賣本公司股份時務請審慎行事。 承董事會命 三愛健康產業集團有限公司 本公告乃由三愛健康產業集團有限公司（「本公司」，連同其附屬公司統稱「本集團」） 根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第13.09條及 香港法例第571章證券及期貨條例（「證券及期貨條例」）第XIVA部項下內幕消息條 文（定義見上市規則）而刊發。 本公司董事會（「董事會」）謹此知會本公司股東（「股東」）及本公司潛在投資者，根據 目前可得資料及對本集團截至二零二五年六月三十日止六個月（「本期間」）的未經審 核管理 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 三愛健康產業集團有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事（「董 事」）會（「董事會」）欣然宣佈，本公司將於二零二五年八月二十八日（星期四）舉行董 事會會議，以（其中包括）考慮及酌情批准刊發本集團截至二零二五年六月三十日止 六個月期間的未經審核中期業績，以及考慮建議派發中期股息（如有）。 承董事會命 三愛健康產業集團有限公司 執行董事 佘昊 Sanai Health Industry Group Company Limited 三愛健康產業集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1889） 董事會召開日期 香港，二零二五年八月十四日 於本公告日期，董事會包括三名執行董事，分別是袁朝陽先生、佘昊先生及謝海京先生；以及三名 獨立非執行董事，分別是朱依諄教授、許麒麟先生及徐婉丹女士。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 三愛健康産業集團有限公司 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01889 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | 本月底法 ...

Financial Performance - Revenue from the pharmaceutical products business decreased by 15.39% to approximately RMB 85.05 million, down from approximately RMB 100.52 million in 2023[19]. - Profit from the pharmaceutical products business fell to RMB 3.68 million, representing a decrease of approximately 81.43% compared to RMB 19.82 million for the corresponding period in 2023[19]. - The Group generated total revenue from continuing operations of approximately RMB85.22 million for the year ended 31 December 2024, representing a decrease of approximately 20.92% compared to RMB107.77 million for the year ended 31 December 2023[47]. - Gross profit for the Group's continuing operations was approximately RMB16.86 million, with a gross profit margin of 19.78% for the year ended 31 December 2024, down from RMB29.22 million and 27.12% in 2023, respectively[52]. - Profit attributable to owners of the Company was approximately RMB4.89 million for the year ended 31 December 2024, representing a decrease of approximately 73.75% compared to RMB18.63 million in the corresponding period in 2023[59]. - Distribution costs for the Group's continuing operations increased to approximately RMB6.25 million in 2024 from approximately RMB0.78 million in 2023, an increase of approximately RMB5.47 million[50]. - Administrative expenses for the Group's continuing operations amounted to approximately RMB26.05 million for the year ended 31 December 2024, an increase of approximately RMB12.66 million from RMB13.39 million in 2023[51]. - The company's profit attributable to owners for the year ended December 31, 2024, was approximately RMB 4.89 million, a decrease of about 73.75% compared to RMB 18.63 million for the same period in 2023[64]. - Basic and diluted earnings per share for the year ended December 31, 2024, were approximately RMB 3.37, down from RMB 14.52 and RMB 12.73 in 2023[65]. Business Operations - The management decided to downsize the production capacity of Fujian Rui Chuang in 2025 due to continuous deterioration in gross profit margin and decreasing sales volume[17]. - A write-off of RMB 1,780,000 and RMB 731,000 was made for Fujian Rui Chuang's property, plant and equipment and right-of-use assets, respectively[17]. - The genetic testing and molecular diagnostic services business was ceased as of June 1, 2024, and reclassified as a discontinued operation[17]. - Fujian Rui Chuang remains the core production center and exclusive sales channel for the Group's developed pharmaceutical products[17]. - The increase in general costs and supply shortages of traditional Chinese herbal materials adversely affected gross profit margins and sales volumes[17]. - The company is focusing on its pharmaceutical products and finance leasing businesses moving forward[17]. - The management is exploring new strategies to mitigate the impact of rising costs and supply chain issues[17]. - Future outlook includes potential market expansion and product development initiatives[17]. - The revenue from the finance leasing business for the Reporting Period was RMB0.17 million, a significant decrease from RMB7.25 million in 2023, due to the expiration of existing contracts and no new contracts being entered into[22]. - As of December 31, 2024, the Group had no customers in the finance leasing business, down from 2 customers on December 31, 2023[22]. - The Group's finance leasing services primarily target the medical, pharmaceutical, and public infrastructure industries, but are not limited to these sectors[23]. - The Group has not entered into any new finance leasing agreements during the Reporting Period, making the weighted average term of finance leases not applicable (2023: 1.6 years)[34]. - The Group completed the disposal of 59% of its shareholding in Zentrogene Bioscience Laboratory Limited for HK$22 million, becoming a 41%-owned associate, to reallocate resources towards its core pharmaceutical business[36]. - Following the divestment of Zentrogene, genetic testing and molecular diagnostic services have been discontinued as a main business segment effective June 1, 2024[37]. - The Group anticipates challenges in business performance due to slower-than-expected economic recovery in China post-Covid, despite a focus on sustainable growth[38]. - The Group will continue to implement cost control measures and maintain a flexible approach to strengthen its revenue base and optimize financial performance[38]. Corporate Governance - The Group's corporate governance practices comply with the Corporate Governance Code during the year ended December 31, 2024, with a noted deviation from provision C.2.1[109]. - The Company has adopted the Model Code for Securities Transactions by Directors, confirming compliance by all Directors during the year ended December 31, 2024[110]. - The Board consisted of eight members as of December 31, 2024, including five executive Directors and three independent non-executive Directors[114]. - The Board convened a total of 5 Board meetings and 2 general meetings during the year ended December 31, 2024[124]. - All independent non-executive Directors confirmed their independence, satisfying the requirements under the Listing Rules[131]. - The Company has complied with the requirements under Rules 3.10 and 3.10A of the Listing Rules, ensuring at least three independent non-executive Directors have appropriate professional qualifications[131]. - The attendance record for executive Directors showed that Mr. She Hao attended all 5 Board meetings, while Mr. Chen Chengqing and Professor Zhang Rongqing did not attend any[127]. - The Board is responsible for enhancing shareholders' value through strategic planning and oversight of the Group's management[115]. - The Company has developed, reviewed, and monitored the code of conduct applicable to directors and employees[122]. - The Board reviewed the Company's policies and practices on corporate governance and made recommendations during the year[122]. - The roles of chairman and chief executive officer are separated, with Mr. She Hao serving as Deputy Chief Executive Officer during the reporting period[128]. - The Board meets at least 4 times a year to review financial performance and other significant matters[117]. - The Board comprises 5 executive Directors and 3 independent non-executive Directors, with male Directors representing approximately 87.5% and female Directors approximately 12.5%[141]. - The Company has maintained and renewed Directors' and Officers' liabilities insurance for all Directors and senior management for the year ended December 31, 2024[152]. - The Board Diversity Policy was adopted in August 2013, aiming to achieve diversity through various factors including age, gender, and professional experience[139]. - The Nomination Committee has set measurable goals regarding age, professional qualification, term of service, and independence to implement the Board Diversity Policy[140]. - The dividend policy emphasizes continuity, stability, and sustainability, with recommendations subject to the Board's discretion based on the Group's earnings per share and financial conditions[151]. - All independent non-executive Directors confirmed their independence in accordance with the Listing Rules[135]. - The Company has achieved gender diversity requirements at the Board level as per Rules 13.92 of the Listing Rules[141]. - The responsibilities of non-executive Directors include regular attendance at meetings and providing independent opinions[136]. - The Company encourages continuous professional development for Directors through training and relevant reading materials[147]. Risk Management and Internal Control - The Group has established risk management and internal control systems to manage strategic, operational, financial, and compliance risks[191]. - An independent professional firm was engaged to assist in the internal audit function and evaluate the effectiveness of the Group's risk management and internal control systems for the year ended December 31, 2024[192]. - The Group conducted an annual risk assessment to identify and prioritize risks for internal audit projects[193]. - The Board acknowledges its responsibility for preparing consolidated financial statements that provide a true and fair view of the Company's state of affairs for the year ended December 31, 2024[185]. - The Nomination Committee reviewed the composition of the Board and the independence of all independent non-executive directors during the review year[178]. - The Company has taken steps to enhance its risk management and internal control systems based on identified control weaknesses[194]. - The Nomination Committee is responsible for evaluating the diversity policy and the appointment of new directors[178]. - The Board is committed to reviewing the effectiveness of the Group's risk management and internal control systems at least annually[196]. - An independent professional internal audit firm has been appointed to assist in evaluating the effectiveness of the risk management and internal control systems for the year ending December 31, 2024[197]. - The Group has conducted an annual risk assessment to identify strategic, operational, financial, and compliance risks associated with its main business operations[196]. - The Audit Committee and the Board believe that the Group has maintained effective and adequate risk management and internal control systems during the year ended December 31, 2024[199]. - The Group has established procedures for handling and disseminating inside information to prevent mishandling within the organization[198]. - All external publications and presentation materials must be reviewed by management before release to ensure accuracy[198]. - The internal audit plan prioritizes identified risks for relevant annual internal audit projects[196]. - The Group aims to enhance its risk management and internal control systems based on findings from the risk assessment and internal control checks[197]. Employee and Shareholder Information - The total staff cost for the group was approximately RMB 16.82 million for the year ended December 31, 2024, compared to RMB 8.14 million in 2023, with an increase in employees from 68 to approximately 164[86]. - The Group employed approximately 164 employees during the reporting period, with total employee costs amounting to RMB 16.82 million[92]. - The Company does not recommend any final dividend for the year ended December 31, 2024, consistent with the previous year[105]. - The total issued shares of the Company was 152,898,695 Consolidated Shares as of December 31, 2024, following a share consolidation effective on 13 August 2024[62]. - As of December 31, 2024, male employees accounted for approximately 59.76% and female employees for approximately 40.24% of the total workforce[142]. - The entire issued share capital of Sanai International was charged as security for the Convertible Notes issued in February 2022[90]. - The initial conversion price of the Convertible Notes was set at HK$0.119 per share, later amended to HK$0.098 per share[99]. - The maturity date of the Convertible Notes was extended by 3 years to February 9, 2026[99]. - The total remuneration paid to the external auditor, Forvis Mazars CPA Limited, for audit services was HK$1,200,000 for the year ended December 31, 2024[184]. - The remuneration for non-audit services related to interim results was HK$100,000, with other non-audit services totaling HK$200,000[184].

BA Sanai Health Industry Group Company Limited 三 愛 健 康 產 業 集 團 有 限 公 司 | --- | --- | --- | --- | |-----------------------------------------------------------------------------------------------------------------------|------------|-------|-------| | | | | | | | | | | | (Incorporated in the Cayman Islands with limited liability) (於同曼群島註冊成立的有限公司) Stock Code 股份代號 : 1889 | Love China | | | | | | | | | Hong KongHong Kong | Yourself | | | | INTERIM REPORT | | | | ２０２４ 中期報告 | --- | --- | |------------------------- ...

Financial Performance - Revenue for the six months ended June 30, 2024, was RMB 36,729,000, a decrease of 40% compared to RMB 61,289,000 for the same period in 2023[2] - Gross profit for the same period was RMB 6,821,000, down 72% from RMB 24,403,000 year-on-year[2] - Net profit for the period was RMB 9,655,000, a decline of 38% from RMB 15,499,000 in the previous year[3] - The company reported a total comprehensive income of RMB 5,230,000, compared to RMB 11,952,000 in the prior year[3] - Basic and diluted earnings per share were both RMB 0.37, down from RMB 0.48 in the same period last year[2] - The group reported a net loss of RMB (909) thousand for the six months ended June 30, 2024, compared to a profit of RMB 22,641 thousand for the same period in 2023[14] - The basic earnings per share attributable to the company's owners for the six months ended June 30, 2024, was RMB 9,971,000, down from RMB 15,543,000 in 2023, indicating a decline of about 35.5%[22] - The diluted earnings per share attributable to the company's owners for the six months ended June 30, 2024, was RMB 12,683,000, compared to RMB 18,029,000 in 2023, reflecting a decrease of approximately 29.5%[22] Assets and Liabilities - Non-current assets increased significantly to RMB 115,688,000 from RMB 14,635,000 as of December 31, 2023[4] - Cash and cash equivalents stood at RMB 340,332,000, slightly up from RMB 332,474,000 at the end of 2023[4] - The company’s total equity rose to RMB 355,341,000 from RMB 269,671,000 year-on-year[6] - The total assets for the reporting segments as of June 30, 2024, amounted to RMB 441,828 thousand, an increase from RMB 380,557 thousand as of December 31, 2023[15] - The company reported a total of RMB 41,840,000 in borrowings as of June 30, 2024, compared to RMB 7,697,000 as of December 31, 2023, indicating a significant increase in debt[31] - The company’s total liabilities increased significantly due to the issuance of new debt instruments and the extension of existing convertible bonds[27][28][31] - The asset-liability ratio as of June 30, 2024, was approximately 32.42%, down from 39.23% as of December 31, 2023[61] Revenue Breakdown - For the six months ended June 30, 2024, the total revenue from external customers was RMB 36,729 thousand, a decrease of 40% compared to RMB 61,289 thousand for the same period in 2023[11] - The revenue from pharmaceutical products was RMB 31,010 thousand, down 37% from RMB 49,146 thousand in the previous year[17] - Revenue from genetic testing and molecular diagnostics services was approximately RMB 57.2 million, a decrease of about 21.2% compared to RMB 72.6 million in the same period of 2023[51] - The financing leasing business generated zero revenue during the period, down from RMB 4.88 million in the same period of 2023, due to the expiration of all existing financing lease contracts[44] Expenses and Costs - Administrative expenses increased by approximately 89.2% to RMB 121.3 million, primarily due to legal and professional fees related to various corporate actions[55] - The company experienced a foreign exchange loss of RMB 4,425,000 related to overseas operations[3] - For the six months ended June 30, 2024, the company's income tax expense was RMB 1,569,000, compared to RMB 4,736,000 for the same period in 2023, representing a decrease of approximately 66.8%[19] Acquisitions and Sales - The company acquired properties, plants, and equipment amounting to approximately RMB 32,931,000 during the six months ended June 30, 2024, while there were no such acquisitions in the same period of 2023[23] - The company completed the sale of 59% equity in Zentrogene Bioscience Laboratory Limited for HKD 22,000,000 (approximately RMB 20,469,000) on May 31, 2024[35] - The company acquired 51% equity in Beijing Hangyang Health Technology Co., Ltd. for RMB 33,150,000, completing the acquisition on May 14, 2024[37] - The identifiable net assets acquired from Beijing Hangyang Group were valued at RMB 61,012,000, with goodwill recognized at RMB 2,034,000[38] - The cash outflow for the acquisition of Beijing Hangyang Group was RMB 28,190,000 after accounting for cash received[38] Shareholder Information - The company did not recommend any dividend payment for the six months ended June 30, 2024, consistent with the previous year[21] - The company’s total issued and paid-up ordinary shares as of June 30, 2024, were 3,822,467, with a total value of RMB 38,224,000[40] - The company has a stock option plan in place to attract and retain employees, with 132,722,250 options available for grant as of June 30, 2024[74] - The company has granted a total of 31,000,000 stock options during the reporting period, with an exercise price of HKD 0.084 and a closing price of HKD 0.078[75] Corporate Governance and Management - The company has complied with the Corporate Governance Code, with three independent non-executive directors providing sufficient checks and balances[82] - The Audit Committee, consisting of three independent non-executive directors, reviewed the group's financial reporting procedures and internal controls, confirming compliance with relevant accounting standards[84] - The company expresses gratitude to the management team and employees for their efforts, which are crucial for the company's sustainable development[86] Legal and Regulatory Matters - The company is currently undergoing a retrial regarding a civil judgment related to a financing lease agreement, with a total claim amount of RMB 33,855,032.69 for overdue rent and additional penalties[78] - The company has filed an appeal against the initial judgment, which has been rejected, and the case has been sent back for retrial[78] Management Changes - The company’s former directors, Mr. Gao and Mr. Xiu, resigned on June 28, 2024[76] - Mr. Gao and Mr. Xiu resigned as executive and non-executive directors effective June 28, 2024, while Mr. Xie was appointed as an executive director on the same date[82]

Financial Performance - The revenue from the pharmaceutical products business decreased by 34.15% to approximately RMB100.52 million in 2023, down from RMB152.65 million in 2022[13]. - Profit from the pharmaceutical products business fell to RMB19.82 million, representing a decrease of approximately 72.05% compared to RMB70.90 million in the corresponding period of 2022[13]. - Revenue from the finance leasing business was approximately RMB7.25 million, down from RMB14.82 million in 2022[17]. - For the year ended December 31, 2023, the Group generated total revenue of approximately RMB122.10 million, representing a decrease of approximately 30.59% compared to RMB175.92 million for the year ended December 31, 2022[46]. - Gross profit for the year ended December 31, 2023, amounted to approximately RMB35.19 million, with a gross profit margin of 28.82%, down from RMB91.68 million and 52.11% in 2022, respectively[53]. - Profit attributable to owners of the Company was approximately RMB18.63 million for the year ended December 31, 2023, representing a decrease of approximately 36.24% compared to RMB29.22 million in 2022[55]. Finance Leasing Business - The number of customers in the finance leasing business decreased from 21 as of December 31, 2022, to only 2 as of December 31, 2023[17]. - The Group did not enter into any new finance leasing contracts in the latter half of 2023 due to a more prudent evaluation approach[17]. - The Group's finance leasing services primarily target the medical, pharmaceutical, and public infrastructure industries[18]. - The Group's finance leasing business is not limited to any particular industry, allowing for potential expansion into other types of devices and equipment[18]. - The revenue generated from finance leasing business during the reporting period was approximately RMB 7.25 million, a decrease from RMB 14.82 million in 2022[20]. - As of December 31, 2023, the group had only two customers in the finance leasing business, down from 21 customers in 2022[20]. - The weighted average term of outstanding finance leases was 1.6 years, compared to 1.4 years in 2022, with all leases requiring repayment by installments[32]. - The Group will continue to adopt a prudent approach in evaluating and granting new finance leasing loans in 2024 due to uncertainties in economic growth and market volatility[44]. - The Group has not entered into any new finance leasing agreements during the reporting period[31]. Cost Management and Challenges - A significant increase in the general cost and a shortage of traditional Chinese herbal materials adversely affected the gross profit margin and sales volume of the pharmaceutical products[10]. - The group expects to face challenges in business performance due to the slower-than-expected economic recovery in China[36]. - The company will rigorously implement cost control measures and maintain a flexible approach to strengthen its revenue base[36]. - The Group plans to expand its sales networks to enhance market penetration despite challenges from rising costs of traditional Chinese herbal materials affecting gross profit margins[42]. Corporate Governance and Board Diversity - The Company aims to achieve board diversity by appointing at least one female Board member by the end of 2024[135]. - The Board has adopted a Board Diversity Policy to enhance strategic objectives and support sustainable development[132]. - The Company has complied with Listing Rules requiring at least three independent non-executive Directors with appropriate qualifications[126]. - The Board reviewed and monitored the training and continuous professional development of Directors and senior management[124]. - The Company has established measurable goals for Board diversity, focusing on age, professional qualification, term of service, and independence[134]. - The Board believes there is sufficient check and balance with three independent non-executive Directors[125]. - The Company actively seeks the opinions of independent non-executive Directors even if they cannot attend meetings in person[120]. - The company adopted a board diversity policy in August 2013 to enhance its strategic goals and sustainable development[136]. - The company considers various factors for board diversity, including age, gender, cultural background, and professional experience[136]. - The company will review its board diversity policy periodically to ensure its effectiveness and progress towards achieving set goals[136]. Audit and Risk Management - The Audit Committee held three meetings during the year and reviewed the effectiveness of the company's internal audit function[156]. - The Audit Committee is responsible for overseeing the company's financial reporting system, financial statements, risk management, and internal control procedures[155]. - The Company conducted an annual risk assessment identifying strategic, operational, financial, and compliance risks across major business operations[191]. - The Audit Committee and the Board reviewed the effectiveness of the Group's risk management and internal control systems, concluding they were effective and adequate for the year ended December 31, 2023[194]. - An independent professional internal auditor firm was engaged to assist in evaluating the effectiveness of the Group's risk management and internal control systems for the year ended December 31, 2023[188]. - The Group has established risk management and internal control systems to manage business risks and provide reasonable assurance against material misstatements or losses[187]. Shareholder Communication and Dividend Policy - The Company maintains good communication with shareholders through various reports and encourages participation in general meetings[200]. - The Board does not recommend any final dividend for the year ended December 31, 2023, consistent with the previous year[95]. - The dividend policy emphasizes continuity, stability, and sustainability, with no assurance that a dividend will be proposed in any specific period[144].

Financial Performance - For the fiscal year ending December 31, 2023, revenue decreased by approximately 30.59% to approximately RMB 122.10 million (2022: RMB 175.92 million) [3] - Gross profit for the same period was approximately RMB 35.19 million (2022: RMB 91.68 million), resulting in a gross margin of approximately 28.82% (2022: 52.11%) [3] - Net profit for the fiscal year was approximately RMB 13.37 million (2022: RMB 35.20 million) [3] - Basic and diluted earnings per share were approximately RMB 0.58 and RMB 0.51 respectively (2022: RMB 0.95 and RMB 0.89) [3] - The company reported other income of RMB 536,000 (2022: RMB 359,000) [6] - Selling expenses decreased to RMB 780,000 from RMB 1.602 million in the previous year [6] - Administrative and other operating expenses were RMB 15.39 million, down from RMB 17.51 million in 2022 [6] - The total comprehensive income for the year attributable to owners of the company was RMB 18.63 million (2022: RMB 29.22 million) [6] - The company’s financial performance indicates a significant decline in profitability and revenue, necessitating strategic reassessment for future growth [4] Revenue and Growth - Total revenue for the year reached RMB 33,192 million, a significant increase from RMB 17,830 million in the previous year, representing an 86% growth [7] - The company reported a net loss of RMB 2,005 million, compared to a net loss of RMB 803 million in the previous year, indicating a worsening financial position [7] - The total comprehensive income for the year was RMB 12,564 million, up from RMB 5,980 million, reflecting a 110% increase [7] - The company experienced a foreign exchange loss of RMB 1,158 million, which impacted overall financial results [7] - Revenue from external customers for the reporting segments reached RMB 122,098 thousand, with a significant contribution from the pharmaceutical segment at RMB 100,517 thousand [31] - Revenue from external customers was RMB 175,923 thousand, indicating a decrease of approximately 30% year-over-year [33] - Revenue from the pharmaceutical segment for 2023 was RMB 100,517 thousand, compared to RMB 152,654 thousand in 2022, reflecting a decline of 34.1% [43] - Revenue from genetic testing and molecular diagnostics services increased to RMB 14,333 thousand in 2023 from RMB 8,450 thousand in 2022, representing a growth of 69.5% [43] Assets and Liabilities - Total assets decreased to 368,805 million RMB from 357,433 million RMB, reflecting a change in financial position [9] - Current liabilities increased to 59,173 million RMB compared to 126,586 million RMB, indicating a significant shift in short-term obligations [9] - Net current assets rose to 309,632 million RMB, up from 230,847 million RMB, showing improved liquidity [9] - Non-current assets, including property and equipment, decreased from 7,590 million RMB to 6,508 million RMB, indicating a reduction in long-term investments [9] - The total liabilities decreased to 59,173 million RMB, down from 126,586 million RMB, reflecting a stronger balance sheet [9] - Total liabilities decreased to 113,769 thousand in 2023 from 128,742 thousand in 2022, a reduction of 11.6% [36] Strategic Initiatives - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives [12] - The company aims to leverage strategic acquisitions to bolster its growth trajectory and market share in the coming fiscal year [12] - The company plans to enhance its digital marketing efforts, aiming for a 40% increase in online sales channels [28] - The company is exploring strategic acquisitions to bolster its technology capabilities, with a budget of $200 million allocated for potential deals [30] - The company plans to adopt a more cautious approach due to the slower-than-expected recovery of the Chinese economy, focusing on expanding production capacity and promoting self-developed pharmaceutical products to increase market share [96] Shareholder and Capital Management - The company does not recommend any dividend payments for the fiscal years ending December 31, 2023, and December 31, 2022 [53] - The company’s total equity attributable to the company's owners rose to RMB 264,449 million, compared to RMB 245,589 million in the previous year, indicating an increase of about 7.6% [10] - The company’s capital and reserves reached RMB 234,584 million, an increase from RMB 215,847 million, reflecting a growth of approximately 8.7% [10] - The company’s market capitalization and stock price have shown significant fluctuations, with a price range of HKD 0.064 to HKD 0.080 during the reporting period [83] Legal and Compliance Matters - The company is liable for a judgment amounting to RMB 33,855,032.69 for unpaid rent under a financing lease agreement [151] - The company has received a civil judgment from the Beijing Fourth Intermediate People's Court regarding a lawsuit filed in 2018 [147] - The lawsuit involves claims for unpaid rent and associated penalties totaling RMB 47,592,982.21 [149] - The company has filed an appeal to the Beijing High People's Court regarding a ruling on January 22, 2021, contesting the validity of a 2016 financing lease agreement and all claims made by the plaintiff [152] Employee and Operational Metrics - The group employed approximately 68 employees during the reporting period, with total employee costs around RMB 11.44 million, down from RMB 18.45 million in 2022 [128] - The company has established several departments and committees to implement work segmentation for the finance leasing business, including approval and review processes [103] - The company’s finance leasing services primarily provide financing for medical devices and rehabilitation equipment, aligning with its existing pharmaceutical products business [99]